 PALO ALTO, Calif., Aug. 5, 2021 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration FDA has granted Breakthrough Therapy Designation for avexitide for the treatment of congenital hyperinsulism HI. 